Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
Altimmune, a clinical-stage biopharmaceutical company, will announce its first quarter 2022 financial results on May 12, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Altimmune, a clinical-stage biopharmaceutical company, will announce its first quarter 2022 financial results on May 12, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its primary candidate being pemvidutide (ALT-801) for obesity and NASH treatment. Additionally, it is developing HepTcell™, aimed at treating chronic hepatitis B.
Positive
- Focus on novel peptide-based therapeutics for significant health issues.
- Lead product candidate pemvidutide (ALT-801) targets obesity and liver diseases.
Negative
- None.
Details
News Market Reaction – ALT
The recorded move for ALT in the trading session of this news was -6.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on May 12 to discuss financial results and provide a business update.
Conference Call Information:
| Date: | Thursday, May 12 |
| Time: | 8:30 am Eastern Time |
| Domestic Dial-in: | (800) 225-9448 |
| International Dial-in: | (203) 518-9708 |
| Conference ID: | ALTQ122 |
| Webcast: | https://edge.media-server.com/mmc/p/j5i9f735 |
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor and Media Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.